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Most outbreaks of Rift Valley fever (RVF) occur in re-
mote locations after ﬂ  oods. To determine environmental risk 
factors and long-term sequelae of human RVF, we exam-
ined rates of previous Rift Valley fever virus (RVFV) expo-
sure by age and location during an interepidemic period in 
2006. In a randomized household cluster survey in 2 areas 
of Ijara District, Kenya, we examined 248 residents of 2 
sublocations, Gumarey (village) and Sogan-Godud (town). 
Overall, the RVFV seropositivity rate was 13% according to 
immunoglobulin G ELISA; evidence of interepidemic RVFV 
transmission was detected. Increased seropositivity was 
found among older persons, those who were male, those 
who lived in the rural village (Gumarey), and those who had 
disposed of animal abortus. Rural Gumarey reported more 
mosquito and animal exposure than Sogan-Godud. Sero-
positive persons were more likely to have visual impairment 
and retinal lesions; other physical ﬁ  ndings did not differ. 
R
ift Valley fever (RVF) is a mosquito-borne zoonosis 
that is expanding its range in Africa and the Middle 
East. Economic effects can be catastrophic for meat and 
dairy producers, e.g., high illness and mortality rates among 
affected livestock herds (1,2) prompting World Organiza-
tion for Animal Health–mandated international embargoes 
of livestock exports. These epidemics are even more dev-
astating for pastoral nomads and local herders; many adult 
animals can die, affecting the next crop of newborns and 
the survival of locals who are economically and physi-
cally dependent on milk and meat during the epidemic. 
During large RVF outbreaks, extensive numbers of human 
infections occur as well, leading to substantial healthcare 
challenges in resource-limited settings. RVF symptoms 
in persons are typically fever, myalgia, and malaise; in a 
noteworthy minority of cases retinitis, encephalitis, hem-
orrhagic fever, and death occur. Overall mortality rate is 
≈1% (3,4). 
RVF is caused by the phlebovirus, Rift Valley fever 
virus (RVFV), which was originally isolated in Kenya and 
is endemic to other countries of East Africa, South Africa, 
and the Senegal River valley (3,5–7). The virus, introduced 
repeatedly into Egypt since the 1970s, and most recently 
into the Arabian peninsula (Yemen and Saudi Arabia) in 
2000 (8–10), is embedded in ecosystems by vertical trans-
mission in certain ﬂ  oodwater Aedes mosquito species (1). 
Consequently, RVF outbreaks are strongly linked to exces-
sive rainfall and local ﬂ  ooding. The most recent Kenyan 
Rift Valley fever outbreak occurred during El Niño rains 
from November 2006 through April 2007 (11,12). The 
largest RVF outbreak in Kenya took place in an El Niño–
related ﬂ  ooding period in 1997–1998 (13). Even within 
different climate zones, RVFV transmission may vary 
considerably as a function of ﬁ  ne-scale differences in local 
environment. 
Evidence of prior RVFV infection can be tested by 
ELISA for anti-RVFV immunoglobulin (Ig) G (14,15). 
Earlier studies have shown that RVFV seroprevalence in 
Kenyan populations has been as high as 32% in high-risk 
areas during epidemics (13). During interepidemic peri-
ods, observed community RVFV seroprevalence rates 
have ranged from 1% to 19% in different settings within 
Kenya (16). 
Because RVF outbreaks typically occur in remote lo-
cations under extreme weather conditions, relatively little 
is known about the underlying health status of at-risk com-
munities. Likewise, debate continues regarding the likely 
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dominant mode of animal-to-human transmission during 
combined epizootics and epidemics. RVFV reemergence, 
caused by ﬂ  oodwater mosquitoes, is followed by wide-
spread ampliﬁ  cation in high-risk animal populations and 
progressively greater prevalence among animals. When 
epizootic conditions are right, additional mosquito species 
will feed on viremic animals and subsequently transmit 
RVFV to humans, creating a potential epidemic. Humans 
can also become infected through exposure to infectious 
animal tissues or bodily ﬂ  uids such as abortus, birthing 
ﬂ  uids, milk, or blood. Among pastoral nomads and other 
herders in the semiarid regions of Africa, family members 
could be differentially exposed depending on traditional 
gender-speciﬁ  c duties, thereby altering the risk-modifying 
effects of age or gender. Speciﬁ  c types of animal exposure 
that are the most risky, and important nonanimal exposures 
have not yet been elucidated. Knowing which forms of ex-
posure provide the greatest RVFV transmission risk may 
be useful for endemic or epidemic public health education 
and for targeting interventions (such as animal vaccination) 
that can decrease infection or illness during an epidemic. 
The goals of this study were to 1) determine the baseline 
human population health status in an area that has suffered 
repeated RVF outbreaks; 2) identify which animal and no-
nanimal exposures are associated with RVFV seropositiv-
ity; 3) evaluate whether seropositivity, exposures, and risks 
differ among town and village settings in a high-risk region 
of northeastern Kenya; and 4) assess whether interepidemic 
human RVFV transmission occurs. 
Materials and Methods
Location
Our study was a location-stratiﬁ  ed household-based 
cluster sampling of human populations residing in 2 areas 
near Masalani Town, Ijara District, situated in a semiarid 
region of Northeastern Province, Kenya. The study was 
performed in March and April 2006, ≈8.5 years after the 
previous RVF outbreak of 1997–1998, and well before the 
ﬂ  oods during the fall of 2006 that were associated with the 
most recent RVF epizootic/epidemic. On the basis of our 
study objectives, the balanced sampling frame for selection 
of the planned 250 participants was divided between a rural 
village, Gumarey (centered at 1° 40′12′′S, 40°10′48′′E), and 
a town, Sogan-Godud (centered at 1°41′24′′S, 40°10′12′′E). 
Both are sublocations deﬁ  ned within the Kenya Census and 
are located within 500 m of each other and within 10 km of 
the Tana River, which is prone to ﬂ  ooding during periods 
of excessive rainfall. Flatness of the local terrain, combined 
with poor drainage, makes the area a prime environment 
for RVFV transmission during ﬂ  oods, as evidenced by on-
going RVF outbreaks. Gumarey has a largely seminomadic 
pastoralist population, and local homes are traditional grass 
huts. Sogan-Godud is a larger town with more permanent 
tin-roofed dwellings and stores (Figure 1).
Population 
Study recruitment was begun after consultation and ap-
proval by local administrators and religious leaders. After 
an initial demographic census was conducted to determine 
the current local population and its distribution, 270 survey 
participants were selected by randomized cluster sampling 
of households in the 2 designated subsections of Masalani 
town. Children <1 year of age and those residing in the area 
<2 years were excluded. All adult participants provided 
informed consent. Parents provided informed consent for 
participating children; children >7 years of age provided 
individual assent. The study sample comprised a locally 
representative ethnic mix of >99% Somali or Bantu and 
<1% Indian or other Asian. Participating households were 
sampled by using a probability proportionate to size ap-
proach. Nonparticipating households were substituted for 
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Figure 1. Photographs depicting differences between sublocations 
in northeastern Kenya. Sogan-Godud (A) has more permanent 
dwellings and stores with tin-roofed buildings. Gumarey (B) has 
more semipermanent traditional dwellings and animal grazing 
areas.RESEARCH
by using additional, randomly-selected households chosen 
according to sampling rules established at the outset of the 
survey.
Examination Procedures 
Study participants received a structured interview re-
garding housing, animal exposure, motor function, visual 
function, and recent or remote RVF-related symptoms 
(questionnaire in online Technical Appendix 1, available 
from www.cdc.gov/EID/content/14/8/1240-Techapp1.pdf; 
accompanying parents served as proxies for children when 
necessary). Participants also received a complete physical 
examination, a vision test and indirect ophthalmoscopic ex-
amination for signs of current or previous retinal inﬂ  amma-
tion, and phlebotomy (i.e., 5 mL venous blood samples from 
persons >5 years of age and 1 mL from children <5). 
Laboratory Testing 
The primary measure of RVFV exposure was sero-
positivity, indicated by serum anti-RVFV IgG detection 
using ELISA. Specimens were screened for the presence 
of anti-RVFV IgG by ELISA by using lysates of Vero cells 
infected with the MP-12 strain (vaccine strain) of RVFV 
as the test antigen and lysates of mock-infected cells as the 
internal control antigen. This assay has been established 
and validated in previous survey studies (15,16). Serum 
samples diluted 1:100 were read at 405 nm; those with an 
optical density (OD) value (corrected for reactivity on nor-
mal cell antigen) > mean + 2 standard deviations for control 
serum and absolute value >0.2 were deemed positive. Each 
sample was run in duplicate, and OD values were averaged. 
Any OD discrepancy between duplicate tests was resolved 
by repeat testing. Pooled RVFV-positive serum samples 
were used as the positive plate controls, and pooled RVFV-
negative North American serum samples were used as the 
negative plate controls. Serologic screening was performed 
at the Division of Vector-Borne Diseases in Nairobi and 
conﬁ  rmed at Case Western Reserve University; correlation 
of results was excellent. Conﬁ  rmatory plaque reduction 
neutralization test (PRNT) was performed at University of 
Texas Medical Branch at Galveston to assess the risk of 
false-positive results secondary to ELISA cross-reactivity 
with related viruses. Conﬁ  rmatory testing using PRNT was 
performed on all positive samples (n = 33) and an age- and 
location-matched set of negative samples (n = 33) (17). All 
ELISA-positive samples had PRNT titers >80; most had 
titers of 320. All but 1 ELISA-negative sample had titers 
<10. This apparently false-negative sample had a PRNT 
titer of 80 on repeated testing.
Statistical Analysis 
Initial univariate analysis was conducted to describe 
demographic variables (online Appendix Table 1, available 
from www.cdc.gov/EID/content/14/8/1240-appT1.htm) 
Bivariate analysis was based on χ2 test (or Yates correc-
tion to the χ2 test where appropriate) of several potential 
predictors of RVFV seropositivity (online Appendix Table 
1) as well as bivariate comparisons between villages (on-
line Appendix Table 2, available from www.cdc.gov/EID/
content/14/8/1240-appT2.htm). After initial bivariate anal-
ysis of RVFV-seropositivity outcomes, predictor variables 
were further tested for association with RVFV seropositiv-
ity by using multivariable logistic regression. Data for all 
248 participants were modeled by using predictor variables 
that had been determined by bivariate analysis to be associ-
ated with RVFV seropositivity (online Technical Appendix 
2, available from www.cdc.gov/EID/content/14/8/1240-
Techapp2.pdf). Logistic models were also constructed by 
village to determine local predictors of RVFV seropositivi-
ty (online Appendix Table 3, available from www.cdc.gov/
EID/content/14/8/1240-appT3.htm). Individual predictors 
were tested for multicolinearity by using χ2 test. Hosmer-
Lemeshow goodness-of-ﬁ  t χ2 values were calculated for 
all logistic models and indicated that model predictors 
sufﬁ  ciently described the observed data (online Technical 
Appendix 2 and online Appendix Table 3). All bivariate 
analysis and logistic modeling was initially performed by 
using R software version 2.3.1 (www.r-project.org/index.
html) and conﬁ  rmed by using SPSS version 15.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). 
Ethical Considerations 
This study was performed under a human research pro-
tocol approved by the Human Investigations Review Board 
of University Hospitals of Cleveland and the Ethical Re-
view Committee of the Kenya Medical Research Institute. 
It is registered as Clinical Trial NCT00287014 and avail-
able from www.clinicaltrials.gov.
Results
Survey Results 
A total of 270 potential participants were invited to 
participate; they were selected by randomized cluster sam-
pling of 66 households in the 2 designated administrative 
sublocations of Masalani Town in Ijara district. Of this se-
lected sample, 248 (91.9%) completed all study procedures, 
including serum testing (online Appendix Table 1). 
The ﬁ  nal study cohort comprised 248 participants, of 
whom 33 (13%, 95% conﬁ  dence interval [CI] 9.3–18.1) 
were RVFV seropositive. Of the 248, 122 (49%) were from 
Gumarey, and of these, 25 (20%, 95% CI 14.0–29.2) were 
seropositive, and 126 (51%) were from Sogan-Godud, 
and of these, 8 (6%, 95% CI 2.7–11.8) were seropositive 
(Figure 2). Of all samples, 118 (47.6%) were from children 
<15 years of age, and 4 of the 118 (3.4%) were seroposi-
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tive. These 4 youngest seropositive participants were 4, 12, 
13, and 14 years of age, and all were long-term permanent 
residents of the study area. Of the 130 adults in the sampled 
cohort, 29 (22.3%) had positive anti-RVFV IgG results; the 
oldest was 81 years of age.
Links between Past Exposure and Seropositivity
Many exposures, both nonanimal and animal, were as-
sociated with RVFV seropositivity (online Appendix Table 
1). In bivariate statistical analyses, RVFV seropositiv-
ity varied signiﬁ  cantly according to the following factors: 
age (participants >15 years of age were more at risk, p = 
0.0001), gender (male participants were more at risk, p = 
0.011), location (those from Gumarey were more at risk, p 
= 0.001), home ﬂ  ooding (p = 0.024); contact with a dead 
human body (p = 0.0001); contact with cattle (p = 0.012); 
and involvement in sheltering (p = 0.003), butchering (p = 
0.0001), skinning (p = 0.0001), cooking (p = 0.005), milk-
ing (p = 0.0001), birthing livestock (p = 0.0001), or dispos-
ing of an aborted animal fetus (p = 0.0001). 
Other reported exposures varied signiﬁ  cantly between 
the 2 sublocation groups. Those from Sogan-Godud were 
more likely to have used mosquito nets (odds ratio [OR] 
5.2, p = 0.0001) and mosquito coils (OR 8.2, p = 0.0001) 
to reduce insect exposure. Those from Gumarey were more 
likely to have had goat contact (OR 2.6, p = 0.046), had cat-
tle contact (OR 4.7, p = 0.0001), consumed raw milk (OR 
4.1, p = 0.0001), sheltered livestock (OR 2.6, p<0.002), 
butchered livestock (OR 1.5, p = 0.0001), birthed livestock 
in the home (OR 2.1, p = 0.005), disposed of a livestock 
fetus (OR 1.7, p = 0.005), or to have had direct contact with 
human remains (OR 2.1, p = 0.026) (Figure 3; online Ap-
pendix Table 2).
The ﬁ  nal logistic model to predict RVFV seropositivity 
included age, location, gender, and disposal of an aborted 
animal fetus (online Technical Appendix 2). In multivari-
able logistic regression models used to predict adjusted odds 
of RVFV seropositivity, location was signiﬁ  cant when age 
and gender were controlled for; those residing in Gumarey 
were at 4 times the risk of those in Sogan-Godud (adjusted 
OR 4.15, 95% CI 1.59–10.87). Seropositivity also varied 
by gender when age and location were controlled for; male 
participants had >3 times the risk of women participants 
(20% vs. 9%; adjusted OR 2.78, 95% CI 1.18– 6.58 for 
male participants vs. female participants), but this differ-
ence did not remain signiﬁ  cant within sublocation analysis. 
After age, gender, and location were controlled for, those 
who had disposed of an aborted animal fetus, were 3 times 
more likely to be seropositive (72.7% vs. 35.7%, adjusted 
OR 2.78, 95% CI 1.03–7.52). Age and location, but not 
gender, were associated with disposal of an aborted animal 
fetus, such that those who were older or who were from 
Gumarey were more likely to dispose of an abortus (online 
Technical Appendix 2). 
Subgroup analysis by village showed signiﬁ  cant pre-
dictors of RVFV seropositivity in Gumarey to be an ill 
family member, disposal of an aborted fetus, and gender 
(online Technical Appendix 2). Displacement by ﬂ  ood was 
also associated with RVFV seropositivity in Gumarey but 
could not be included in the model because every seroposi-
tive participant was displaced by ﬂ  oods and this factor was 
overdetermined. Male participants were >3 times as like-
ly to be seropositive compared with female participants: 
(adjusted OR 3.45, 95% CI 1.17–10.19). Disposal of an 
aborted animal fetus (adjusted OR 15.12, 95% CI 4.445–
51.35) and presence of an ill family member (adjusted OR 
18, 95% CI 1.35–246.97) were also associated with RVFV 
seropositivity. In Sogan-Godud, the logistic model to pre-
dict seropositivity included age, such that the odds of se-
ropositivity increased 5% for every 1-year increase in age 
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Figure 2. Flowchart of northeastern Kenya Rift Valley fever virus 
study participants.
Figure 3. Exposures between northeastern Kenyan villages differed; 
Gumarey had more animal exposure and Sogan-Godud had more 
mosquito control. *p<0.05; †p<0.01; ‡p<0.001 (by χ2 test).
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(adjusted OR 1.05, 95% CI 1.019–1.091) (online Technical 
Appendix 2). 
Children <15 years of age had a much lower risk for 
RVFV seropositivity than those >15 years of age. The ad-
justed OR for seropositivity (calculated from the overall lo-
gistic model) was 1.05; 95% CI 1.03–1.07 per year of age 
(Figure 4). This difference persisted at the sublocation level 
with those children in Sogan-Godud still with signiﬁ  cantly 
lower risk than adults.
Symptom History and Physical Examination Findings
Symptoms and signs reported on the survey question-
naire included fever, malaise, myalgia, chills, backache, 
eye pain, headache, rash, red eyes, photophobia, poor ap-
petite, ﬂ  ushing, nausea, vomiting, meningismus, poor vi-
sion, epistaxis, hematemesis, hematochezia, bruising, con-
fusion, vertigo, stupor, and coma. Of these, a past history 
of myalgias (OR 6.03, p = 0.0001), backache (OR 3.86, p = 
0.003), eye pain (OR 2.28, p = 0.034), red eyes (OR 2.75, 
p = 0.008), meningismus (OR 2.97, p = 0.004), poor vi-
sion (OR 2.74, p = 0.008), and coma (OR 14.55, p = 0.005) 
were statistically associated with RVFV seropositivity in 
the study population (online Appendix Table 4, available 
from www.cdc.gov/EID/content/14/8/1240-appT4.htm). 
Upon physical examination, no nonocular ﬁ  nding was spe-
ciﬁ  cally associated with RVFV seropositivity.
Ophthalmologic Findings 
Of the 18 identiﬁ  ed cases of substantial retinal disease 
in the survey population, 7/18 (38.9%) were seropositive 
compared with 11/18 (61.1%) who were seronegative (p = 
0.003, χ2 8.75). All participants with eye disease were >21 
years of age, and all seropositive participants with eye dis-
ease were >50 years of age. The OR of late eye disease as-
sociated with RVFV exposure (seropositivity) was 4.99 (p 
= 0.003) (online Appendix Table 5, available from www.
cdc.gov/EID/content/14/8/1240-appT5.htm). Measured vi-
sual acuity ranged from 6/5 to 6/60 (equivalent to 20/17–
20/200) in the seronegative group and 6/5–6/36 (20/17–
20/120) in the seropositive group, although both groups 
included those with extremely poor vision who could de-
cipher only large objects (measured by ﬁ  nger counting) or 
who could not perceive light. Visual acuity differed statis-
tically among groups and was more likely to be worse in 
the RVFV–seropositive group (visual impairment deﬁ  ned 
as >20/80: 12% of seronegative vs. 25% of seropositive 
participants; p = 0.047, χ2 3.94). Among the 18 participants 
with retinal disease, 14 (78%) had visual impairment, and 
among the 7 seropositive participants with retinal disease, 5 
(71%) had visual impairment. No distinctive lesion was as-
sociated with RVFV seropositivity, though the eye diseases 
differed among the groups. Seropositive participants with 
eye disease had of optic atrophy (3), retinal hemorrhage 
(2), and retinal scarring (3). One person had retinal hemor-
rhage and scarring. By contrast, seronegative participants 
with eye disease had uveitis (1), vasculitis (1), maculopa-
thy (3), peripapillitis (1), retinal scarring (1), optic scarring 
(2), retinal atrophy (1), and retinal degeneration (1).
Discussion
This study highlights the variability in RVFV sero-
prevalence in high-risk settings. In northeastern Kenya, 
older age, rural village location, male gender, disposal 
of an aborted fetus, and eye disease were associated with 
RVFV seropositivity. RVFV seropositivity was relatively 
high in our sample population in Masalani town, Kenya, 
particularly in the village area (Gumarey), where seroposi-
tivity rates were nearly 4 times higher than in the town area 
(Sogan-Godud); these areas were separated by only 500 m. 
Clues to the reasons for this discrepancy in seroprevalence 
were identiﬁ  ed in our study. Those from Gumarey were 
more likely to have mosquito and animal exposures than 
those from Sogan-Godud. These risk factors, coupled with 
the most important predictors of rural seropositivity, male 
gender, and disposal of an aborted animal fetus, yield evi-
dence for disparate risks for RVFV infection in different 
communities. 
As identiﬁ  ed in our prior work, RVFV seroprevalence 
can vary signiﬁ  cantly across Kenya (16). Our current study 
shows that large seroprevalence discrepancies can also oc-
cur over short distances. Spatial risk assessments of RVF 
in animals in Senegal have been predicted by using mea-
surements of seasonal rainfall, land surface temperature, 
distance to perennial water bodies, and time of year (18). 
Designing such risk maps with human risk factor data may 
enable improved surveillance systems and better predic-
tion of the spatial distribution of RVFV. This information, 
gathered with satellite imagery (19) and large-scale cluster 
analysis (20), can be used not only to predict large outbreaks 
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but also to identify local hot spots of RVFV transmission to 
optimize RVF control in resource-limited settings.
For each year of life, the odds of being RVFV sero-
positive increased by 5%. Male participants were nearly 3 
times more likely to be seropositive than female partici-
pants, a risk that was noted in the 1997 RVF outbreak in-
vestigation (13). The difference in seropositivity among 
genders is not explained on the basis of reported animal 
or nonanimal exposures, which were comparable and not 
statistically different between genders. The increased sero-
positivity among male participants may have a biological 
basis, given that outcome of infection and resultant im-
mune response to other viruses have been linked to gender 
differences (21). 
Disposal of an aborted animal fetus was associated with 
nearly 3 times increased odds of RVFV seropositivity. This 
ﬁ  nding may indicate the importance of RVFV transmission 
by aerosolization of blood and amniotic ﬂ  uid during animal 
birthing. It is unknown whether aerosol or vector-borne 
transmission is the dominant form of transmission during 
interepidemic or epidemic periods. Our analysis indicates 
that disposal of an aborted animal fetus was a common as-
sociated risk factor at both the composite and sublocation 
level. Planned repeat sampling of our cohort since the most 
recent outbreak of 2006–2007 may enable the determina-
tion of the primary mode of epidemic transmission. 
We found evidence of interepidemic human transmis-
sion of RVFV, which has not been previously shown. Our 
validation of seropositive young children, born after the 
documented outbreak in 1997–1998, indicate that low-level 
interepidemic transmission to humans is continuing in the 
Masalani area and likely in other areas of Kenya (16). The 
natural reservoir for RVFV and the mechanism by which 
humans become infected during interepidemic periods are 
unknown. Wild animals have been shown to be infected 
with RVFV, but further studies must determine whether 
these animals play a role in RVFV maintenance between 
outbreaks (22).
We demonstrated statistically signiﬁ  cant differences 
between the seropositivity rates of those with and with-
out eye disease. Those with chronic retinal disease were 
5 times more likely to be RVFV seropositive. We did ob-
serve a difference in visual acuity between RVFV seroposi-
tive and seronegative persons in our sample tested 8 years 
after the 1997–1998 outbreak, and perhaps greater changes 
may have been present during acute RVF disease. Although 
there were no ocular ﬁ  ndings that were pathognomonic for 
prior RVFV infection, the detected retinal disease supports 
evidence from previous studies on the oculopathogenesis 
of RVFV (23). 
No speciﬁ  c nonocular examination ﬁ  nding was associ-
ated with RVFV seropositivity, but several reported symp-
toms were statistically more common among those who 
were RVFV seropositive. Most of these symptoms were 
severe neurologic manifestations of disease, such as neck 
stiffness, confusion, and coma. RVFV can cause encephali-
tis (1), and this type of inﬂ  ammation may explain the higher 
prevalence of these reported symptoms among seropositive 
participants. Myalgia and backache may be present in most 
of the nonsevere RVF cases and are not speciﬁ  c to RVFV 
infection. Poor vision, which was noted to be more com-
mon among RVFV seropositive participants in our sample, 
may be an indicator for RVF retinitis, a common sequela of 
RVFV infection (23,24).
RVFV IgG ELISA and PRNT antibodies are believed 
to last decades after infection and therefore provide a re-
liable index of prior RVFV exposure. In contrast, though 
less well studied, it appears that IgM is lost in 50% of pa-
tients after 45 days and is absent in 100% by 4 months af-
ter infection (25). We did not perform IgM testing in our 
study, although it might have yielded useful additional 
information about acute RVFV infection. We also recog-
nize that seropositive results may be false positive due to 
cross-immunoreactivity with viruses in the same family, 
although discrepancies between the neutralization test and 
the ELISA were only 4.9% in this population. The use of 
conﬁ  rmatory PRNT testing of ELISA-positive samples can 
greatly improve viral speciﬁ  city (26). 
Our study was limited by its cross-sectional design; 
therefore, we are unable to conclude whether the identi-
ﬁ  ed risk factors speciﬁ  cally caused RVFV exposure. The 
validity of the associations in this study relies on accurate 
recall of exposures by the study participants. Although we 
asked about timing of symptoms and exposures, language 
differences during questioning limited our accurate collec-
tion of these data. Our study may have limited generaliz-
ability; we tested risk factors from a small population in 
Masalani, and risks may vary in other parts of Kenya or in 
other countries. Data on animal exposures were collected 
in a binary fashion, so no information about magnitude or 
duration of contact is known, which may have an effect on 
risk estimations. We also had no quantitative exposure data 
for the RVFV vectors in our study area.
This study highlights the large-scale variability in ex-
posure and RVFV seropositivity among Kenyan villages 
and emphasizes the effect of age, gender, location, and 
animal husbandry in RVFV transmission. This informa-
tion is useful for local public health agencies so that they 
can target protective interventions according to risk factors 
in different populations. Further studies are needed to ex-
amine the epidemiologic, biological, and genetic basis for 
the increased risk among persons of male gender and to 
quantify the potential public health impact of modifying 
the rural environment. RVFV transmission is known to be 
ongoing in livestock in areas where RVFV is endemic dur-
ing interepidemic periods; we have shown that this extends 
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to humans, conﬁ   rming past observations (27). Ongoing 
efforts to predict hot spots of infection on both small and 
large scales is useful only when at-risk communities are 
able to use the information to target mosquito or vaccine 
control efforts and prevent outbreaks. As RVF expands its 
geographic range and becomes recognized as a disease of 
global importance for human and animal health, more re-
search is needed to deﬁ  ne the most accessible modes of 
transmission control.
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